Phase 2 KRAS P.G12C trials recruiting now

All KRAS P.G12C trials, every phase

Phase 2 KRAS P.G12C trials

• A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
  NCT06008288 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
  NCT05398094 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
  NCT05288205 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
  NCT05631249 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.